Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, a functionally selective muscarinic (M1) agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well-tolerated in healthy young adult males, as well as in healthy elderly males and females.

The purpose of the Phase I trial was to investigate the safety, tolerability and pharmacokinetics of multiple doses of NGX267 and to confirm data from previous studies in which NGX267 demonstrated evidence of muscarinic receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ages of 18 and 55, were enrolled in the double-blind, placebo-controlled trial conducted at one center in Belgium. In a series of sequential dosing cohorts, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once-daily for four consecutive days. NGX267 was well tolerated at doses up to and including 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances. TorreyPines plans to initiate a Phase II dose-ranging trial in CIAS during the first half of 2008.

A secondary objective was to obtain quantitative measures of salivary flow, prior to and at multiple time points post-dosing, as a peripheral biomarker for stimulation of the muscarinic receptor. In the study, increases in peak and total sal
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 Research ... the addition of the "Arthroscopy Devices ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of ... the world market for Arthroscopy Devices. The ... impacting the market for these products. , ...
(Date:5/21/2015)... 2015  Cardica, Inc. (Nasdaq: CRDC ) today announced ... , the company,s vice president of operations, was granted an ... at a per share exercise price of $0.43, the closing ... granted pursuant to Cardica, Inc.,s Inducement Plan, which was approved ... Rule 5653(c)(4) of the Nasdaq Global Market for equity grants ...
(Date:5/21/2015)... May 21, 2015 The Pharmaceutical Care ... the Medicare Part D offsets included in the ... "If the 21st Century Cures initiative can ... premier health program – Medicare – then its ... down the road. "Leveraging payments to ...
Breaking Medicine Technology:Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Cardica Announces New Employment Inducement Grant 2
... 22, 2011 Prasco Laboratories, the Authorized Generics company, ... Shionogi Inc . Under the terms of the ... Nitrofurantoin Oral Suspension, the Authorized Generic version of Furadantin® Oral ... U.S. under the Prasco label. "Prasco is ...
... ("MGT", "we", or "the Company") (AMEX: MGT ), a ... following update on recent developments at the Company and its majority-owned ... a summary of its recently filed financial results (via SEC Form ... 2011. Highlights: On ...
Cached Medicine Technology:Prasco® Launches Authorized Generic with Shionogi Inc. 2MGT Capital Investments, Inc. Provides Update on Recent Developments 2MGT Capital Investments, Inc. Provides Update on Recent Developments 3MGT Capital Investments, Inc. Provides Update on Recent Developments 4MGT Capital Investments, Inc. Provides Update on Recent Developments 5MGT Capital Investments, Inc. Provides Update on Recent Developments 6
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley Medical ... 29, 2015 at 11 a.m., followed by a community celebration ... set to officially open on June 1, 2015, is located ... “The opening of Mountain Point Medical Center is an exciting ... Kent Loosle, CEO of Mountain Point Medical Center. “Mountain Point ...
(Date:5/22/2015)... NS (PRWEB) May 22, 2015 Following ... a sale agreement with US-based health brand Nature’s Way, ... Skin brand. Retention of Ascenta Skin is an integral ... is excited about this opportunity to further develop Ascenta ... , Ascenta Skin is a breakthrough, anti-aging skincare ...
(Date:5/22/2015)... Island, NY (PRWEB) May 22, 2015 ... announces that June 17, 2015, the Annual One Day ... place. Since 2007, Hands On HCMT offers drastically reduced certificates ... therapists and estheticians have enough sessions, through what used to ... it is wonderful for the community as well. This once ...
(Date:5/22/2015)... 22, 2015 Carnegie Science Center ... announced a new partnership to develop BodyTech, a dynamic, ... The initiative includes a new exhibit at the Science ... theater, and a new traveling science show, Anatomy Adventure, ... 2015. , Designed to explore a wide range ...
(Date:5/22/2015)... According to a new Aegis Living Study ... as likely to worry about what will happen to their ... Boomers, 69% Silent Generation), which may help explain why nearly ... aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). ... 2015 among more than 2,000 U.S. adults ages 18+. ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... dangerous characteristics of cancer is its ability to metastasize, or ... major need for better tests to detect cells that break ... the body. Effective identification of these cells, referred to ... improve quality of life for many cancer patients. A commentary ...
... 16, 2010 The AIUM is pleased to ... AIUM to endorse the recent AIUM Training Guidelines ... guidelines allow for a several practitioners, including physicians, ... ultrasound examinations, marking significant promise for the future ...
... ... Healthcare, 89 percent of physicians agree that patients receiving negligent treatment deserve fair compensation. ... Alpharetta, GA (Vocus) March 16, ... of physicians agree that patients receiving negligent treatment deserve fair compensation. , , , , ...
... Many with severe peripheral arterial disease can avoid amputation, ... When angioplasty fails, patients with severe peripheral arterial disease ... placed in the blocked artery below the knee might ... limb ischemia, the most severe form of peripheral arterial ...
... taking Plavix before surgery died soon after than those ... (HealthDay News) -- In a trial comparing two anti-clotting ... less likely to die than those given Plavix, researchers ... forming clots, but Plavix, the more popular drug, has ...
... President and CEO Dr. Richard Merkin , was featured on several segments throughout the day on Fox National News and Fox Business Channel discussing current healthcare payment structures ... ... ... ...
Cached Medicine News:Health News:Revisiting the need to detect circulating tumor cells 2Health News:Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 3Health News:Stenting May Save Legs 2Health News:Stenting May Save Legs 3Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3Health News:Lakeside Medical Group, Heritage Provider Network, CEO Dr. Richard Merkin, Featured on Several Segments of Fox National News and Fox Business Channel on Current Healthcare Payment Structures to Physicians 2Health News:Lakeside Medical Group, Heritage Provider Network, CEO Dr. Richard Merkin, Featured on Several Segments of Fox National News and Fox Business Channel on Current Healthcare Payment Structures to Physicians 3
... Post Operative Pin® Knee Brace (DxHDDLP) has a ... drop lock lever and laminate liner. The precision ... brace from migrating on the leg during ambulation. ... that controls flexion and extension in 5° increments ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Drytex Adjustable Patella Donut ... a unique nylon core and polyester ... airflow. A trimable full-circumference donut provides ... who have neoprene based allergies or ...
... for total knees, meniscus repairs, regenerative chondroplasty, ... TROM gives easy-to-use range of motion control ... Rehab TROM can be used as a ... purchased separately be used with the TROM ...
Medicine Products: